- EAA Brochure
- EAA Initial Contact Letter
- EAA Calendar of Events
- EAA Media Kit
- Understanding Eczema
- Children Eczema
- Teenage Eczema
- Adults Eczema
- Bleach Baths
- Hand Washing
- Wet Wrapping
- Cortisone Creams
- Dry Skin
- Ear Eczema
- Infections & Eczema
- Red Skin Syndrome
- Winter Skin Tips
The first biologic treatment for atopic eczema offers real hope to those living with more severe eczema
Dupilumab* (Dupixent®) is a new ‘biologic’ treatment for severe eczema which works in a different way to the other drugs that are currently available for eczema. Biologic drugs are produced by genetically modified organisms such as bacteria or cells cultured in a laboratory. They have been used to treat severe years. Dupilumab is the first biologic treatment for atopic eczema and is taken subcutaneously (under the skin). There are other biologic treatments for atopic eczema that are currently undergoing research.
How does it work?
Chemical messengers in the body called interleukins (ILs) allow the different parts of our immune system to communicate and help fight off harmful viruses and bacteria. The immune system of people with inflammatory conditions like atopic eczema overreacts to allergens (eg dust, mould, pollen). This triggers the production of certain ILs, which cause greater inflammation. It is this chronic inflammation that leads to symptoms of eczema such as red, itchy, dry patches on the skin.
Biologics works by blocking ILs from binding to their cell receptors (protein molecules that receive chemical signals from outside a cell); this stops the immune system from overreacting. Dupilumab works on two specific ILs thought to contribute to atopic conditions: IL-4 and IL-13. By Blocking IL-4 and IL-13 from binding to their cell receptors, dupilumab limits to the overreaction of the immune system, dampening down the chronic inflammatory response and lessening the symptoms of atopic eczema.
If you think of a chemical messenger such as IL-4 as a key, and a cell receptor as lock, a biologic drug works in a similar way to fixing a coin over the keyhole so that the key (IL-4) is unable to get into the lock (the cell receptor).
Immunosuppressive drugs for eczema (eg ciclosporin) suppress many different chemical messengers that control inflammation, whereas biologic drugs suppress just one or two of these chemical messengers and have fewer potential side effects than conventional immunosuppressive drugs.
What has the research shown?
Clinical trials of dupilumab have shown that it produces a meaningful reduction in the severity of eczema, as well as a reduction in the body surface affected by eczema in the majority of patients. Many patients receiving dupliumab also experience a reduction in itching and an improvement in sleep and quality of life. The trial data results showed that many patients taking dupilumab no longer needed to apply as much topical steroid while taking the drug.
Is it available?
Dupilumab is available in Australia.*
Who is it for?
Dupilumab is licensed for the treatment of children from 12 years of age and adults with moderate-to-severe atopic dermatitis (atopic eczema) who are possible candidates for systemic therapy. It is unlikely that anyone whose eczema is not at the severe end of the spectrum will be considered for dupilumab. To be eligible for dupilumab you will need to have tried at least one immunosuppressive drug (eg azathioprine, ciclosporin, methotrexate or mycophenolate mofetil) and the drugs needs to have not worked effectively for you. You may also be eligible for dupilumab if you have been found to be ineligible for immunosuppressive drugs, for example, if it is known that your body will not worked effectively for you. You may also be eligible for dupilumab if you have been found to be ineligible for immunosuppressive drugs, for example, if it is known that your body will not tolerate them. Dupilumab is significantly more expensive than other drugs currently available for eczema, which might make it more difficult to access.
How do I go about getting it?
If you think you might be eligible for dupilumab, speak to your dermatologist about the possibility of trying it. It will not be offered by GP; you will need to be referred to see a specialist dermatologist.
How is it administered?
Dupilumab is given by injection under the skin once every two weeks. A single syringe and needle delivers one dose. Unlike other drugs treatments for eczema, patients are able to administer dupilumab themselves after having received appropriate training from a healthcare professional.
How long do you take it for?
Dupilumab is an ongoing treatment rather than a treatment that is used for a fixed amount of time. Patients would be expected to show a significant reduction in eczema symptoms and an improvement in quality of life after having taken dupilumab for 16 weeks; If the eczema has not responded adequately to dupilumab after 16 weeks, the treatment may be stopped.
Can people taking dupilumab still use topical steroids and emollients?
Yes, patients taking dupilumab will be expected to use topical steroids and emollients to manage their eczema alongside dupilumab.
What are the risk of dupilumab?
Common side effects of dupilumab include eye inflammation (especially conjunctivitis), headaches and cold sores. People who have asthma as well as eczema could experience a worsening of their asthma symptoms if they stop taking dupilumab is better than that of immunosuppressive drugs.
Can children take dupilumab?
Dupilumab is not currently available for children outside of a clinical trial. It is very unlikely that dupilumab will be available for children before 2020, if not later.
NICE: Dupilumab for treating moderate-to-severe atopic dermatitis: www.nice.org.uk/guidance/TA534.
*Dupilumab is available on private script. The PBAC recommended the listing of dupilumab for the treatment of patients aged 12 years and older with severe atopic dermatitis who are inadequately controlled on topical therapies in April 2020. The PBAC has previously acknowledged the significant reduction in the extent of disease and improved patient quality of life with dupilumab over standard of care in a therapeutic area of high clinical need.